The study states that it will increase in the use of slimming drugs among patients with bariatric surgery

The new test results show a significant increase in the use of slimming drugs among patients undergoing metabolic and bariatric surgery, signaling evolution in the treatment of obesity and type 2 diabetes.

The research will be presented at the American College of Surgeons (ACS) clinical congress in Chicago, October 4-7.

There is no universal approach to the treatment of obesity, metabolic syndrome or diabetes and related conditions. We enter the new world of multidisciplinary care paths and a new boundary of weight management, which is important for patients and surgeons. ”

Patrick J. Sweigert, MD, senior author of the study and a surgeon of bariatrics and resignation with Ohio State University Wexner Medical Center, Columbus, Ohio

The research team conducted a cross -sectional test glucagon-ponplists of the PepTy-1 receptor (GLP-1S) receptor Semglutide (Wegova, Ozmpic) and Dziew (Zepbound, Mounjaro) among patients undergoing metabolic and bariatric surgery. Dr. Sweigert and colleagues analyzed almost 365,000 patients who underwent original metabolic and bariatric surgery in 2018–2024. They used the Kosmos Epic database, which includes over 300 million records of patients from institutions throughout the country to examine prescription patterns for semaglutide and tybrzepatid, two latest GLP-1S on the market.

Key arrangements

• Preliminary results indicate that the percentage of patients receiving at least one GLP -1 prescription in the year preceding the operation increased from 1.8% in the first quarter of 2020 to 29.4% in the fourth quarter of 2024 – sixteen blood cells. The use increased in patients with and without diabetes, emphasizing the expanding role of these drugs in the treatment of obesity, regardless of the status of diabetes.

• Among patients without type 2 diabetes, the preoperative use of GLP-1 has increased by eleven times in the last three years from 2.1% in the first quarter of 2022 to 23.2% in the fourth quarter of 2024. Patients with type 2 diabetes It increased four times, from 11.3% to 45.2% in the same period.

The median age of patients was 43 years, the preoperative median body mass index (BMI) of these patients was 46. Women constituted 80% of the sample, and 33% had a diagnosis of type 2 diabetes.

The main author of Stefan C. Rohde, MD, a resident of general surgery at Ohio State University Wexner Medical Center, noticed that the discoveries reflect the change in a way that candidates of bariatric surgery perceive their treatment options.

“While patients previously thought that they had to choose between the GLP-1 receptor agonists and the operation, we now see that people use both,” said Dr. Rohde. “We know that patients can use GLP-1 after bariatric surgery to strengthen weight loss. But all this is still very new in terms of effective patient management.”

In the future, she added that real data, such as those from Epic Cosmos, can support the study based on evidence of guidelines regarding when to start, combine or go between attempts to treatment, whether before surgery or during the postoperative period.

Researchers recognized the restrictions in their analysis, including potential data inaccuracies in health documentation and uncertainty as to whether patients had completed or taking prescribed medicines.

The co-author of the research is Mahmoud Abdel-Rasoul, MS, MPH.